Resources/
Press Releases
Featured Press
Press Releases
January 8, 2026
Press Release: PHIL Invests in State-of-the-Art Cash Dispense Capabilities
PHIL Inc. today announced a significant expansion of its cash dispense capabilities, a major strategic investment that positions the company to continue serving the rapidly growing direct-to-patient (DTP) market, helping pharmaceutical companies get medications in the hands of patients at scale.
January 8, 2026
Press Release: PHIL and Tenpoint Pharmaceuticals Partner to Launch YUVEZZI™ Direct-to-Patient Cash Program
Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., an all-in-one digital hub and Direct-to-Patient platform, today announced the launch of a Direct-to-Patient (DTP) cash program for YUVEZZI™, the first and only dual-agent prescription eye drop FDA-approved for the treatment of presbyopia.
January 8, 2026
Press Release: PHIL and Sprout Pharmaceuticals Expand Their Affordable Direct-to-Patient Access Program for Addyi(flibanserin)
PHIL, the technology-powered patient access platform designed to help patients get easy and affordable access to their prescribed medications, and Sprout Pharmaceuticals, today announced that they have expanded Sprout's direct-to-patient program for Addyi (flibanserin).
September 22, 2025
Press Release: PHIL Launches Direct-to-Patient 2.0 Platform to Transform Access, Affordability, and Adherence in Pharma
PHIL, a leader in patient access solutions for the life sciences industry, today announced the launch of PHIL Direct, its Direct-to-Patient (DTP) 2.0 platform, designed to help pharmaceutical brands meet evolving patient expectations while navigating affordability, compliance, and policy pressures.
July 8, 2025
Press Release: PHIL Secures $60M Growth Capital from K2 HealthVentures to Accelerate AI Integration
Phil, a leading software-driven pharmaceutical commercialization platform, today announced a $60 million growth debt financing from K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm. The funding will accelerate the integration of artificial intelligence across Phil's platform and support continued customer expansion across a broad range of therapeutic areas.
Create a Path to Commercial Success
Our expert team can build a tailored access program that drives your brand goals.
Corporate Headquarters
14500 N Northsight Blvd, Suite 307, Scottsdale, AZ 85260
